Search clinical trials for: NY-ESO-1 157-165 (165V)

Total 186 results

H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Melanoma (Skin)

United States
Shenzhen University General Hospital

Recruiting

Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma

Advanced Soft-tissue Sarcoma

China
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center

Completed

Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Ludwig Institute for Cancer Research

Completed

Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer

Prostate Cancer

Switzerland, Germany
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute

Completed

Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Ludwig Institute for Cancer Research
NYU Langone Health

Completed

NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors

Tumors

United States
Sun Yat-sen University
Guangdong Xiangxue Precision Medical Technology Co., Ltd.

Recruiting

Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
ImmunoFrontier, Inc.

Completed

Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer

Esophageal Cancer

Japan
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccination During Lymphoid Reconstruction

Intraocular Melanoma | Melanoma (Skin)

United States
Instituto de Investigação em Imunologia
Butantan Institute

Unknown

Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)

Cancer. | Melanoma. | Ovarian Cancer. | Lung Cancer.

Brazil
Ludwig Institute for Cancer Research
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; New York...

Completed

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Sarcoma | Esophageal Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer

United States
Ludwig Institute for Cancer Research
Institute of Cancer Research, United Kingdom

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Melanoma

United Kingdom, Australia, New Zealand
Ludwig Institute for Cancer Research
Mie University

Completed

Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

Stomach Cancer | Breast Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer

Japan
Baylor College of Medicine
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer

Prostate Cancer

United States
University of Arkansas

Completed

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

Multiple Myeloma

United States
Centre Hospitalier Universitaire Vaudois
Ludwig Institute for Cancer Research

Completed

Immunotherapy of Stage III/IV Melanoma Patients

Melanoma

Switzerland
Centre Hospitalier Universitaire Vaudois
Immutep S.A.S.

Terminated

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

Melanoma

Switzerland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy

Sarcoma

United States
Penn State University

Withdrawn

A Vaccine Study for High Risk Cancers

Neuroblastoma | Osteogenic Sarcoma | Rhabdomyosarcoma
Arcturus Therapeutics, Inc.

Recruiting

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

COVID-19 | Corona Virus Infection | SARS-CoV-2 Infection

United States, Singapore
Nina Bhardwaj
Cancer Research Institute, New York City

Completed

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

Tumors

United States
Sun Yat-sen University
Guangdong Xiangxue Precision Medical Technology Co., Ltd.

Active, not recruiting

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Soft Tissue Sarcoma | Bone Sarcoma

China
Columbia University
National Cancer Institute (NCI)

Terminated

Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma

Sarcoma

United States
University of Pennsylvania
Parker Institute for Cancer Immunotherapy; Tmunity Therapeutics

Terminated

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Melanoma | Multiple Myeloma | Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Eunice Kennedy Shriver... and other collaborators

Completed

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 (NYM)

Childhood Solid Neoplasm | Metastatic Neoplasm | Adult Solid Neoplasm

United States
Ludwig Institute for Cancer Research
Cancer Research Institute, NY, USA

Terminated

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Unresectable or Metastatic Melanoma

United States, Australia
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

Melanoma (Skin)

United States
Georgetown University
United States Department of Defense

Suspended

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Ovarian Cancer Stage 3

United States
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute; New York University Cancer Institute

Completed

Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Ludwig Institute for Cancer Research
Cancer Research Institute (CRI)

Completed

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Malignant Melanoma

United States
Catherine Anne Chappell
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

Hepatitis C, Chronic

United States
Takeda

Completed

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children

Norovirus

Finland, Panama, Colombia
Johnson & Johnson Vision Care, Inc.

Completed

Evaluating Soft Contact Lens Prototypes for Myopia Control

Visual Acuity

China
National Cancer Institute (NCI)

Terminated

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cell Cancer

United States
M.D. Anderson Cancer Center

Recruiting

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Myeloma

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

Chemotherapy-Induced Nausea and Vomiting
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions
Memorial Sloan Kettering Cancer Center

Completed

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cancer | Recurrent Ovarian Cancer | Fallopian Tube

United States
Ludwig Institute for Cancer Research
Austin Health; Peter MacCallum Cancer Institute

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma

Melanoma

Australia
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Transitional Cell Carcinoma

United States
Fundacion Oncosur

Completed

Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer (neurabrax)

Breast Cancer

Spain
Renmin Hospital of Wuhan University
Yichang Central People's Hospital; Wuhan Central Hospital; Wuhan No.1 Hospital; Xiangyang Central Hospital and other collaborators

Active, not recruiting

Early Administration of Heparin at FMC for PPCI of STEMI Patients (HELP-PPCI)

STEMI | Primary PCI

China
GlaxoSmithKline

Completed

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma (NY-ESO-1)

Neoplasms

United States
Riley Bove, MD

Recruiting

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (ReWRAP)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
M.D. Anderson Cancer Center

Recruiting

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
Shenzhen Second People's Hospital
Shenzhen Institute for Innovation and Translational Medicine

Unknown

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Melanoma | Breast Cancer | Multiple Myeloma | Ovarian Cancer | Lung Cancer | Neuroblastoma | Bladder Carcinoma | Synovial Sarcoma | Esophagus Carcinoma | Other Metastatic Solid Cancers

China
Dr. Reddy's Laboratories Limited

Completed

Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults

Healthy

United States
Nina Bhardwaj
Cancer Research Institute, New York City; Ludwig Institute for Cancer Research and other collaborators

Completed

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Melanoma

United States

Search clinical trials for: NY-ESO-1 157-165 (165V)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations